Invesco Ltd. Arcellx, Inc. Transaction History
Invesco Ltd.
- $516 Billion
- Q4 2024
A detailed history of Invesco Ltd. transactions in Arcellx, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 26,550 shares of ACLX stock, worth $1.71 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26,550
Previous 22,940
15.74%
Holding current value
$1.71 Million
Previous $1.92 Million
5.59%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ACLX
# of Institutions
223Shares Held
45.1MCall Options Held
434KPut Options Held
433K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$281 Million12.7% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$241 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$226 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$224 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$214 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.82B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...